Cepheid

The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.

The deal covers SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR diagnostic products in certain European nations.

The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio. 

The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.

The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.

The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.

Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.

The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.

Pages

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.